Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Primary central nervous system lymphoma (also called PCNSL, primary CNS lymphoma, or primary brain lymphoma) is defined in the packet as a non-Hodgkin or Hodgkin lymphoma that arises in the brain or spinal cord as a primary lesion, with no evidence of lymphoma outside the central nervous system at the time of diagnosis. The packet lists spinal cord lymphoma, central nervous system non-Hodgkin lymphoma, and cerebral lymphoma as related subtypes. It is catalogued in Orphanet and GARD. The packet does not certify prevalence, onset, or inheritance.
The packet contains no curated phenotype annotations for this condition, and no characteristic findings or age-of-onset categories are recorded. Specific symptoms are therefore not described here.
The packet lists no known genes, no inheritance patterns, and no OMIM entries for this condition, so the genetic basis is not described in this packet. The definition characterizes the disease as a lymphoma that originates within the brain or spinal cord.
The packet does not include diagnostic methods, GeneReviews diagnostic criteria, or newborn screening information for this condition. The only diagnostic-related statement available is the definition, which specifies that no lymphoma is evident outside the central nervous system at the time of diagnosis.
The packet lists no FDA-approved treatments and no foundational therapy or GeneReviews management entries for this condition. It records orphan drug designations, which are regulatory designations and do not indicate approval. Designations with indications naming central nervous system lymphoma include emavusertib, tirabrutinib, and two compounds identified by chemical name. Others, including busulfan and thalidomide, carry broader primary brain malignancy indications. Diaziquone has a WITHDRAWN status and an astrocytoma indication.
98 trials found
Natural history and prognosis are not certified in this packet, and no GeneReviews clinical description is available. Prognosis is therefore not described here.
The packet certifies that ClinicalTrials.gov contains active trial records associated with this condition. Listed examples include CAR T-cell studies, a placebo-controlled tirabrutinib maintenance study in primary CNS lymphoma in complete remission (JCOG2104), a tafasitamab with lenalidomide study in relapsed CNS lymphoma, and an epcoritamab with ibrutinib study in CNS lymphoma. Several listed studies cover broader B-cell malignancies. Its publication-landscape summary identifies diagnostic and biomarker work as the most common research type.
Data assembled from 5 of 12 sources · Last updated Nov 17, 2026, 6:42 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
AI-curated news mentioning primary central nervous system lymphoma
Updated Sep 23, 2026
A new study explores plasma proteomics as a tool for prognostic stratification in patients with newly diagnosed primary central nervous system lymphoma. This research could enhance patient management and treatment outcomes.
A systematic review and meta-analysis evaluates the efficacy and safety of chimeric antigen receptor T-cell therapy in treating primary central nervous system lymphoma. The findings contribute to understanding potential therapeutic options for this rare malignancy.
A recent population-based cohort study investigates survival outcomes and prognostic factors in patients with primary central nervous system low-grade B-cell lymphoma. The findings contribute valuable insights into patient management and treatment strategies for this rare lymphoma subtype.
A study reveals significant racial and socioeconomic disparities affecting survival outcomes in patients with primary central nervous system lymphoma (PCNSL) in the US. The analysis highlights systemic barriers to care and treatment heterogeneity, emphasizing the need for urgent action to address these disparities.
FDA approves ScinoPharm Taiwan’s glatiramer acetate injection for relapsing multiple sclerosis, marking the first complex injectable generic approval for this therapy. Additionally, Alkermes receives breakthrough therapy designation for alixorexton, an oral treatment for narcolepsy type 1.